Terms: = Breast cancer AND CEACAM5, CEA AND Clinical Outcome
17 results:
1. Triple peptide vaccination as consolidation treatment in women affected by ovarian and breast cancer: clinical and immunological data of a phase I/II clinical trial.
Antonilli M; Rahimi H; Visconti V; Napoletano C; Ruscito I; Zizzari IG; Caponnetto S; Barchiesi G; Iadarola R; Pierelli L; Rughetti A; Bellati F; Panici PB; Nuti M
Int J Oncol; 2016 Apr; 48(4):1369-78. PubMed ID: 26892612
[TBL] [Abstract] [Full Text] [Related]
2. Vitronectin: a promising breast cancer serum biomarker for early diagnosis of breast cancer in patients.
Hao W; Zhang X; Xiu B; Yang X; Hu S; Liu Z; Duan C; Jin S; Ying X; Zhao Y; Han X; Hao X; Fan Y; Johnson H; Meng D; Persson JL; Zhang H; Feng X; Huang Y
Tumour Biol; 2016 Jul; 37(7):8909-16. PubMed ID: 26753956
[TBL] [Abstract] [Full Text] [Related]
3. Circulating tumor cells (CTCs) detected by triple-marker EpCAM, CK19, and hMAM RT-PCR and their relation to clinical outcome in metastatic breast cancer patients.
Zhao S; Yang H; Zhang M; Zhang D; Liu Y; Liu Y; Song Y; Zhang X; Li H; Ma W; Zhang Q
Cell Biochem Biophys; 2013 Mar; 65(2):263-73. PubMed ID: 22990361
[TBL] [Abstract] [Full Text] [Related]
4. Clinicopathological and molecular characterization of colorectal micropapillary carcinoma.
Verdú M; Román R; Calvo M; Rodón N; García B; González M; Vidal A; Puig X
Mod Pathol; 2011 May; 24(5):729-38. PubMed ID: 21336262
[TBL] [Abstract] [Full Text] [Related]
5. Molecular detection of micrometastatic breast cancer in histopathology-negative axillary lymph nodes fails to predict breast cancer recurrence: a final analysis of a prospective multi-institutional cohort study.
Fisher CS; Cole DJ; Mitas M; Garrett-Meyer E; Metcalf JS; Gillanders WE; Mikhitarian K; Urist MM; Mann GB; Doherty G; Herrmann VM; Hill AD; Eremin O; El-Sheemy M; Orr RK; Valle AA; Henderson MA; Dewitty RL; Sugg SL; Frykberg E; Yeh K; Bell RM; Baker MK
Ann Surg Oncol; 2010 Oct; 17 Suppl 3():312-20. PubMed ID: 20853052
[TBL] [Abstract] [Full Text] [Related]
6. Synuclein gamma predicts poor clinical outcome in colon cancer with normal levels of carcinoembryonic antigen.
Liu C; Dong B; Lu A; Qu L; Xing X; Meng L; Wu J; Eric Shi Y; Shou C
BMC Cancer; 2010 Jul; 10():359. PubMed ID: 20604972
[TBL] [Abstract] [Full Text] [Related]
7. Detection of cytokeratin 19, human mammaglobin, and carcinoembryonic antigen-positive circulating tumor cells by three-marker reverse transcription-PCR assay and its relation to clinical outcome in early breast cancer.
Chen Y; Zou TN; Wu ZP; Zhou YC; Gu YL; Liu X; Jin CG; Wang XC
Int J Biol Markers; 2010; 25(2):59-68. PubMed ID: 20586026
[TBL] [Abstract] [Full Text] [Related]
8. Development of a multimarker assay for early detection of ovarian cancer.
Yurkovetsky Z; Skates S; Lomakin A; Nolen B; Pulsipher T; Modugno F; Marks J; Godwin A; Gorelik E; Jacobs I; Menon U; Lu K; Badgwell D; Bast RC; Lokshin AE
J Clin Oncol; 2010 May; 28(13):2159-66. PubMed ID: 20368574
[TBL] [Abstract] [Full Text] [Related]
9. Chemosensitivity and stratification by a five monoclonal antibody immunohistochemistry test in the NSABP B14 and B20 trials.
Ross DT; Kim CY; Tang G; Bohn OL; Beck RA; Ring BZ; Seitz RS; Paik S; Costantino JP; Wolmark N
Clin Cancer Res; 2008 Oct; 14(20):6602-9. PubMed ID: 18927301
[TBL] [Abstract] [Full Text] [Related]
10. Intensive post-operative follow-up of breast cancer patients with tumour markers: cea, TPA or CA15.3 vs MCA and MCA-CA15.3 vs cea-TPA-CA15.3 panel in the early detection of distant metastases.
Nicolini A; Tartarelli G; Carpi A; Metelli MR; Ferrari P; Anselmi L; Conte M; Berti P; Miccoli P
BMC Cancer; 2006 Nov; 6():269. PubMed ID: 17116247
[TBL] [Abstract] [Full Text] [Related]
11. Cerebrospinal fluid tumor marker levels in predicting response to treatment and survival of carcinomatous meningitis in patients with advanced breast cancer.
Kosmas C; Tsavaris NB; Tsakonas G; Soukouli G; Gassiamis A; Mylonakis N; Karabelis A
Med Sci Monit; 2005 Aug; 11(8):CR398-401. PubMed ID: 16049383
[TBL] [Abstract] [Full Text] [Related]
12. clinical evaluation of a panel of mRNA markers in the detection of disseminated tumor cells in patients with operable breast cancer.
Varangot M; Barrios E; Sóñora C; Aizen B; Pressa C; Estrugo R; Lavigna R; Musé I; Osinaga E; Berois N
Oncol Rep; 2005 Aug; 14(2):537-45. PubMed ID: 16012742
[TBL] [Abstract] [Full Text] [Related]
13. Changes of cerebrospinal fluid tumor marker levels may predict response to treatment and survival of carcinomatous meningitis in patients with advanced breast cancer.
Kosmas C; Tsavaris NB; Soukouli G; Gouveris P; Tsakonas G; Katselis J; Alexopoulos H; Mylonakis N; Karabelis A
Med Oncol; 2005; 22(2):123-8. PubMed ID: 15965274
[TBL] [Abstract] [Full Text] [Related]
14. Re-evaluation of HER2 status in metastatic breast cancer and tumor-marker guided therapy with vinorelbine and trastuzumab.
Stemmler HJ; Stieber P; Lässig D; Heinemann V
Onkologie; 2005 Feb; 28(2):95-7. PubMed ID: 15692222
[TBL] [Abstract] [Full Text] [Related]
15. Novel mouse model for carcinoembryonic antigen-based therapy.
Chan CH; Stanners CP
Mol Ther; 2004 Jun; 9(6):775-85. PubMed ID: 15194045
[TBL] [Abstract] [Full Text] [Related]
16. Gallbladder carcinomas: an immunoprognostic evaluation of P53, Bcl-2, cea and alpha-fetoprotein.
Kanthan R; Radhi JM; Kanthan SC
Can J Gastroenterol; 2000 Mar; 14(3):181-4. PubMed ID: 10758414
[TBL] [Abstract] [Full Text] [Related]
17. Tissue carcinoembryonic antigen and oestrogen receptor status in breast carcinoma: an immunohistochemical study of clinical outcome in a series of 252 patients with long-term follow-up.
Mauri FA; Caffo O; Veronese S; Verderio P; Boracchi P; Bonzanini M; Rossi N; Perrone G; Dalla Palma P; Barbareschi M
Br J Cancer; 1998 May; 77(10):1661-8. PubMed ID: 9635845
[TBL] [Abstract] [Full Text] [Related]
